Chrome Extension
WeChat Mini Program
Use on ChatGLM
VIPCreated with Sketch.
Research Interests

Papers共 113 篇Author StatisticsCo-AuthorSimilar Experts

By YearBy Citation主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
Survivorship in Advanced Lung Cancer: Understanding a New Landscape and Opportunities
Carolyn J Presley, Nicole Dalal, Ashley P Davenport, Ashnee Gounden,Kavitha Ramchandran,Emily Tonorezos
American Society of Clinical Oncology educational book/Educational bookno. 3 (2024)
Cited0Views0WOSBibtex
0
0
Phase II Trial of Regorafenib and Oral Methotrexate in Previously Treated Advanced KRAS-Mutant NSCLC
Jacqueline Aredo,Heather A. Wakelee,Kavitha J. Ramchandran,Joel W. Neal,Maximilian Diehn, Angela Bik-Yu Hui, Ameen Salahudeen,Bernice Kwong,Gerald J. Berry,H. Henry Guo,Kristen Cunanan,Shireen Vali, Danny Pancirer, Vivian Tsang,Grace Hwang, Monica Loza, Brittany Johnson, Isabelle Blanchard,Sukhmani K. Padda
JTO CLINICAL AND RESEARCH REPORTSno. 12 (2024)
Cited0Views0WOSBibtex
0
0
Effect of De Novo Co-Mutations on Clinical Outcomes in Patients Receiving First-Line Osimertinib for EGFRMutated NSCLC
F. Sun, M. K. Banwait, A. Herrmann,Z. Piotrowska, K. Yun,L. A. Bazhenova,H. A. Wakelee,J. W. Neal, M. S. Das,K. J. Ramchandran,M. Roy,M. Diehn, N. J. Myall
JOURNAL OF THORACIC ONCOLOGYno. 10 (2024): S196-S197
Cited0Views0Bibtex
0
0
P1.12A.10 Effect of De Novo Co-Mutations on Clinical Outcomes in Patients Receiving First-Line Osimertinib for EGFR-Mutated NSCLC
F. Sun, M.K. Banwait, A. Herrmann,Z. Piotrowska, K. Yun,L.A. Bazhenova,H.A. Wakelee,J.W. Neal, M.S. Das,K.J. Ramchandran,M. Roy,M. Diehn, N.J. Myall
Journal of Thoracic Oncologyno. 10 (2024): S196-S197
Cited0Views0Bibtex
0
0
Load More
Author Statistics

#Papers: 113

#Citation: 1674

H-Index: 20

G-Index: 40

Sociability: 6

Diversity: 3

Activity: 85

  • 合作者
  • 学生
  • 导师
No result temporarily, you can search similar Scholar with the same research interest
Data Disclaimer
The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn